drugset / Trial / NCT03637816

Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer

NCT03637816 ↗

Phase 2/3 Active not recruiting 25 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
RandomizedParallel-groupDouble-blindSupportive care

Summary

This phase II/III trial studies how well anamorelin hydrochloride works in reducing anorexia in patients with non-small cell lung cancer that has spread to other places in the body. Anamorelin hydrochloride may help to improve patients' appetite in order to stop weight loss.

Timeline

Start
2018-11-27
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Anamorelin Small molecule 100 mg Oral